Grazoprevir, Elbasvir, and Ribavirin for Chronic Hepatitis C Virus Genotype 1 Infection After Failure of Pegylated Interferon and Ribavirin With an Earlier-Generation Protease Inhibitor: Final 24-Week Results From C-SALVAGE: Table 1.-Reference-Cited by-同舟云学术

Grazoprevir, Elbasvir, and Ribavirin for Chronic Hepatitis C Virus Genotype 1 Infection After Failure of Pegylated Interferon and Ribavirin With an Earlier-Generation Protease Inhibitor: Final 24-Week Results From C-SALVAGE: Table 1.

Published:2015-09-14 Issue:1 Volume:62 Page:32-36
ISSN:1058-4838
Container-title:Clinical Infectious Diseases
language:en
Short-container-title:Clin Infect Dis.

Author:

Buti Maria,Gordon Stuart C.,Zuckerman Eli,Lawitz Eric,Calleja Jose L.,Hofer Harald,Gilbert Christopher,Palcza John,Howe Anita Y. M.,DiNubile Mark J.,Robertson Michael N.,Wahl Janice,Barr Eliav,Forns Xavier

Funder

Merck & Co, Inc

Publisher

Oxford University Press (OUP)

Subject

Infectious Diseases,Microbiology (medical)

Link

http://academic.oup.com/cid/article-pdf/62/1/32/7451888/civ722.pdf

Reference15 articles.

1. American Association for the Study of Liver Diseases, Infectious Diseases Society of America. Recommendations for testing, managing, and treating hepatitis C. Available at: http://www.hcvguidelines.org . Accessed 25 April 2015.

2. Resistance-Associated Variants in Chronic Hepatitis C Patients Treated with Protease Inhibitors

3. Analysis of boceprevir resistance associated amino acid variants (RAVs) in two phase 3 boceprevir clinical studies

4. Evolution of Treatment-Emergent Resistant Variants in Telaprevir Phase 3 Clinical Trials

5. Clinical relevance of HCV antiviral drug resistance

Cited by 88 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Retrospective Cohort Study: Safety and Effectiveness of Elbasvir/Grazoprevir ± Ribavirin Compared With Ombitasvir/Paritaprevir/Ritonavir/Dasabuvir ± Ribavirin in Patients With Chronic Hepatitis C Genotype 1 Infection;Frontiers in Pharmacology;2021-09-09

2. Virological Factors Associated with Failure to the Latest Generation of Direct Acting Agents (DAA) and Re-Treatment Strategy: A Narrative Review;Viruses;2021-03-08

3. Elbasvir and grazoprevir for the treatment of hepatitis C;Expert Review of Anti-infective Therapy;2021-01-17

4. Prophylaxe, Diagnostik und Therapie der Hepatitis-C-Virus(HCV)-Infektion;Zeitschrift für Gastroenterologie;2020-11

5. Utilization and effectiveness of elbasvir/grazoprevir and adoption of resistance-associated substitutions testing in real-world treatment of hepatitis C virus genotype 1A infection: results from the German Hepatitis C-Registry;European Journal of Gastroenterology & Hepatology;2020-05-15